• Industry news
• Ophthalmology

Inspire Completes Patient Enrollment in Three Late-Stage Clinical Trials in Cystic Fibrosis, Dry Eye and Blepharitis

DURHAM, N.C.-- November 4, 2009-- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today patient enrollment is complete in three of its late-stage clinical trials. more

Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon (October 2009)

LOUISVILLE, Ky., Oct. 23, 2009 -- Potentia Pharmaceuticals, a privately-held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), announced today that it has entered into licensing and purchase option agreements with Alcon Research, Ltd., a wholly-owned subsidiary of Alcon, Inc. (NYSE: ACL). The agreements provide Alcon with a license to develop Potentia's leading drug candidate, POT-4, for the treatment of AMD. The agreements also provide for... more

Search the Pharmalicensing Industry news by keyword. Alternatively our advanced search allows you to query by category and therapeutic target.
Category	Therapeutic target
Deals and Alliances Development Financial Results Financings Intellectual Property Regulatory	Cardiovascular Dermatology Endocrine and Metabolic Gastroenterology Genitourinary Hematology Immunology and Allergy Infection Musculoskeletal Neurology Obstetrics and Gynecology Oncology Ophthalmology Psychiatry Pulmonary
To choose more then one item on the list hold CTRL button while selecting. To deselect items press CTRL button and deselect.

Most Viewed

Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon (October 2009)

Inspire Completes Patient Enrollment in Three Late-Stage Clinical Trials in Cystic Fibrosis, Dry Eye and Blepharitis